{"id":"W2168063883","doi":"10.1093/annonc/mdt571","title":"Improved outcomes in elderly patients with metastatic castration-resistant prostate cancer treated with the androgen receptor inhibitor enzalutamide: results from the phase III AFFIRM trial","year":2014,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":128,"is_retracted":false,"has_abstract":false,"ca_institutions":"BC Cancer Agency","funders":"Janssen Pharmaceuticals; Amgen; Astellas Pharma; Association for Federal Information Resources Management","keywords":"Enzalutamide; Medicine; Prostate cancer; Hazard ratio; Placebo; Internal medicine; Population; Docetaxel; Adverse effect; Progression-free survival; Urology; Confidence interval; Oncology; Androgen receptor; Chemotherapy; Cancer; Pathology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005718435,0.0002241275,0.0006227794,0.00006066926,0.0001131121,0.00002234833,0.000140976,0.00007648967,0.00004204429],"category_scores_gemma":[0.0001793805,0.0000908219,0.00007068413,0.0002900487,0.000315983,0.0000931803,0.00002637245,0.0002589135,0.000002551311],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0001000542,"about_ca_system_score_gemma":0.000592367,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.003582569,"about_ca_topic_score_gemma":0.006076887,"domain_scores_codex":[0.9980567,0.00034365,0.0005116739,0.0003438966,0.0003659364,0.0003781668],"domain_scores_gemma":[0.9979712,0.0007902512,0.0003715105,0.0003568377,0.0004015779,0.00010857],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.8480211,0.003980683,0.02871776,0.00004139901,0.001549441,0.00005474835,0.005229273,0.00002182298,0.004690451,0.0000150085,0.003938972,0.1037393],"study_design_scores_gemma":[0.797111,0.1054197,0.0417252,0.0003201197,0.000700726,0.000002901702,0.001811506,0.0001541735,0.03208898,0.00004721239,0.02022964,0.0003888287],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9805026,0.0002495416,0.00000238421,0.01544462,0.00007815722,0.002909887,0.0006629644,0.000016099,0.0001337159],"genre_scores_gemma":[0.9979202,0.0001425712,0.00009485568,0.0004538099,0.00009905735,0.0004555304,0.0003852526,0.00002400068,0.0004247215],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.1033505,"threshold_uncertainty_score":0.5415797,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.0580529218207753,"score_gpt":0.3790785064417077,"score_spread":0.3210255846209324,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}